Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier López Jiménez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, Sherida Woei-A-Jin

Blood (2024) 144 (Supplement 1): 867.

https://doi.org/10.1182/blood-2024-199271

Published: 2024

Journal Articles

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Johannes Duell, Diana Alvarez Arias, Hilka Rauert-Wunderlich, Florian Eisele, Alla Volgina, Beth Rumberger, Thomas Stauffer Larsen, Andreas Rosenwald

Blood (2024) 144 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2024-199176

Published: 2024

Journal Articles

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Blood (2024) 144 (Supplement 1): 3792.4.

https://doi.org/10.1182/blood-2024-206735

Published: 2024

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2024-202348

Published: 2024

Journal Articles

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Xiang Zhou, Sarah Wiethe, Angelika Wolff, Max J Steinhardt, Nazia Afrin, Mara John, Christine Riedhammer, Xianghui Xiao, Umair Munawar, Julia Mersi, Seungbin Han, Johannes Waldschmidt, Angela Riedel, Max S. Topp, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Leo Rasche

Blood (2024) 144 (Supplement 1): 4705.

https://doi.org/10.1182/blood-2024-203391

Published: 2024

Journal Articles

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Jennifer Wing Lam Cheung, Prachurjya Panda, Xiang Zhou, Katrin Sinning, Ankit Agrawal, Andy Shing Fung Chan, Johannes Duell, Johannes Waldschmidt, Hermann Einsele, Martin Väth, Andreas Rosenwald, Dominic Grün, Leo Rasche

Blood (2024) 144 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2024-203052

Published: 2024

Journal Articles

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Johannes Duell, Alexander M. Leipold, Silke Appenzeller, Viktoria Fuhr, Hilka Rauert-Wunderlich, Matteo Da Via, Oliver Dietrich, Christophe Toussaint, Fabian Imdahl, Florian Eisele, Nazia Afrin, Lars Grundheber, Hermann Einsele, Niels Weinhold, Andreas Rosenwald, Max S. Topp, Antoine-Emmanuel Saliba, Leo Rasche

Blood (2024) 143 (8): 685–696.

https://doi.org/10.1182/blood.2023021672

Published: 2024

Includes: Supplemental data

Journal Articles

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Xiang Zhou, Vivien Wagner, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Mara John, Lukas Scheller, Umair Munawar, Seungbin Han, Johannes M Waldschmidt, Max S. Topp, Johannes Duell, Hermann Einsele, Angela Riedel, Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 95.

https://doi.org/10.1182/blood-2023-180534

Published: 2023

Journal Articles

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Florian Eisele, Nazia Afrin, Emilia Stanojkovska, Mara John, Moutaz Helal, Lars Grundheber, Philipp Weis, Christine Riedhammer, Sofie-Katrin Kadel, Max Steinhardt, Johannes Duell, Johannes M Waldschmidt, Hermann Einsele, Angela Riedel, K. Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2023-189042

Published: 2023

Journal Articles

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Sven Schimanski, Hannah Hornburger, Sofie-Katrin Kadel, Anna Marie Ruckdeschel, Florian Eisele, Daniela Schneider, Anke Heidemeier, Andreas Buck, Rudolf Werner, Johannes M Waldschmidt, Paula Tabares, Andreas Beilhack, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Max S. Topp, Leo Rasche

Blood (2023) 142 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2023-188501

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, Martin Dreyling, Gianluca Gaidano, Nagesh Kalakonda, Eva Maria Gonzalez Barca, Anna Marina Liberati, Zsolt Nagy, Daniel Moik, Mirko Vukcevic, Aasim Amin, Abhishek Bakuli

Blood (2023) 142 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2023-174043

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski

Blood (2023) 142 (16): 1348–1358.

https://doi.org/10.1182/blood.2023020637

Published: 2023

Includes: Supplemental data

Journal Articles

Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma

Moutaz Helal, Mara John, Emilia Stanojkovska, Greta Mattavelli, Lars Grundheber, Alexander Leipold, Nazia Afrin, Christine Riedhammer, Johannes Duell, Max Johannes Steinhardt, Julia Mersi, Hermann Einsele, Kai Kretzschmar, K. Martin Kortuem, Angela Riedel, Leo Rasche

Blood (2022) 140 (Supplement 1): 7060–7061.

https://doi.org/10.1182/blood-2022-168700

Published: 2022

Journal Articles

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Johannes Duell, Wojciech Jurczak, Anna Marina Liberati, Janusz Halka, Esther Pena Carbó, Pau Abrisqueta Costa, Kami J. Maddocks, Martin Dreyling, Andreas Rosenwald, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Blood (2022) 140 (Supplement 1): 6596–6598.

https://doi.org/10.1182/blood-2022-159983

Published: 2022

Journal Articles

First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Johannes Duell, Katerina Kopeckova, Marek Trneny, Christiane Pott, Mouhamad Khouja, John M. Burke, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Derek Blair, David Belada

Blood (2022) 140 (Supplement 1): 3731–3733.

https://doi.org/10.1182/blood-2022-163160

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik

Blood (2022) 140 (Supplement 1): 12108–12109.

https://doi.org/10.1182/blood-2022-157596

Published: 2022

NARROW

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only